SCHEDULE: Satterfield Boosts OS Therapies Stake to 9.4%

Thomas A. Satterfield, Jr. has increased his beneficial ownership in OS Therapies Incorporated to 9.4% of common stock, including convertible preferred shares and warrants.

Summary

• Thomas A. Satterfield, Jr. beneficially owns an aggregate of 3,115,681 shares of OS Therapies Incorporated common stock.
• This ownership represents 9.4% of the company's common stock outstanding.
• The calculation of the percentage is based on 28,097,697 shares outstanding as of May 13, 2025, and an additional 3,764,995 shares sold as reported on July 14, 2025.
• The total beneficial ownership includes 1,943,806 common shares, 558,034 shares of Series A Senior Convertible Preferred Stock (convertible on a one-for-one basis), and 613,841 warrants to purchase common stock at an initial exercise price of $3.00 per share.
• Mr. Satterfield holds sole voting and dispositive power over 296,930 shares, and shared voting and dispositive power over 2,818,751 shares.

Sentiment

Score: 7

Explanation: The increase in beneficial ownership by Thomas A. Satterfield, Jr. to 9.4% of OS Therapies Incorporated's common stock, including convertible preferred shares and warrants, indicates a strong vote of confidence and a long-term investment perspective from a significant individual investor.

Positives

• A significant increase in beneficial ownership by Thomas A. Satterfield, Jr. to 9.4% suggests strong confidence in OS Therapies Incorporated's future prospects.
• The inclusion of convertible preferred stock and warrants indicates a long-term investment strategy and potential for further equity conversion, signaling a deeper commitment.

Negatives

• The filing itself does not present explicit negative aspects related to the company's performance or outlook.

Risks

• The value of the Series A Preferred Stock and Warrants is subject to the conversion ratio and exercise price, which may be adjusted, introducing potential dilution or changes in ownership value.
• The exercise of warrants at $3.00 per share implies a potential future cash outflow for the investor to realize the common stock, which could be a risk if the stock price falls below the exercise price.

Future Outlook

The filing does not provide forward-looking statements or guidance from the company or the reporting person regarding OS Therapies Incorporated's future performance or strategic direction.

Industry Context

This filing is a standard disclosure of significant beneficial ownership, common in the financial industry for transparency. It does not provide specific industry trends or competitive analysis.

Related Party Transactions

• 196,429 common shares, 178,571 Series A Preferred shares, and 196,429 warrants are held by Tomsat Investment & Trading Co., Inc., a corporation controlled by Mr. Satterfield, where he serves as President.
• 319,197 common shares, 290,178 Series A Preferred shares, and 319,197 warrants are held by A.G. Family L.P., a partnership managed by a general partner controlled by Mr. Satterfield.
• 375,000 common shares are held by Caldwell Mill Opportunity Fund, LLC, a fund managed by an entity of which Mr. Satterfield owns a 50% interest and serves as Chief Investment Manager.
• 943,750 common shares are held by Satterfield Vintage Investments, L.P., where Tomsat Investment & Trading Co., Inc. and A.G. Family L.P. jointly own a majority of equity, and Tomsat Investment & Trading Co., Inc. is the general partner.

Stakeholder Impact

• Shareholders: The increased stake by a significant investor may be perceived positively, signaling confidence in the company's future and potentially attracting further investor interest.
• Company Management: Awareness of a large, active shareholder may influence strategic decisions and corporate governance, potentially aligning interests with a major investor.

Key Dates

Recommendation

The filing indicates a significant increase in beneficial ownership by Thomas A. Satterfield, Jr., reaching 9.4% of OS Therapies Incorporated. This substantial stake, including convertible preferred stock and warrants, suggests a strong vote of confidence from a key investor. While this is a positive signal, the Schedule 13G filing primarily discloses ownership and does not provide comprehensive financial performance data or strategic updates necessary for a 'buy' or 'sell' recommendation. Therefore, a 'hold' recommendation is appropriate, acknowledging the positive investor sentiment without sufficient new fundamental information to alter a current position.

Keywords

OS Therapies, Thomas A. Satterfield Jr., Schedule 13G, Beneficial Ownership, Common Stock, Preferred Stock, Warrants, SEC Filing, Investment, Shareholder Stake